Profile
Zung To currently works at Kezar Life Sciences, Inc., as Senior VP-Clinical Development from 2023.
Mr. To also formerly worked at Abgenix, Inc., as Manager, Jazz Pharmaceuticals, Inc., as Vice President-Global Clinical Operations, Syntex Pharmaceuticals Ltd., as Manager, and Kronos Bio, Inc., as Vice President-Clinical Operations from 2020 to 2023.
Mr. To received his undergraduate degree from the University of California, Davis.
Zung To active positions
| Companies | Position | Start |
|---|---|---|
| KEZAR LIFE SCIENCES, INC. | Chief Tech/Sci/R&D Officer | 01/05/2023 |
Former positions of Zung To
| Companies | Position | End |
|---|---|---|
| KRONOS BIO, INC. | Corporate Officer/Principal | 01/05/2023 |
Syntex Pharmaceuticals Ltd. | Corporate Officer/Principal | - |
Abgenix, Inc.
Abgenix, Inc. BiotechnologyHealth Technology Develops therapeutic products | Corporate Officer/Principal | - |
Jazz Pharmaceuticals, Inc.
Jazz Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets pharmaceutical products | Corporate Officer/Principal | - |
Training of Zung To
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 6 |
|---|---|
Abgenix, Inc.
Abgenix, Inc. BiotechnologyHealth Technology Develops therapeutic products | Health Technology |
Jazz Pharmaceuticals, Inc.
Jazz Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets pharmaceutical products | Health Technology |
University of California, Davis
University of California, Davis Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Syntex Pharmaceuticals Ltd. | |
Kezar Life Sciences, Inc.
Kezar Life Sciences, Inc. BiotechnologyHealth Technology Discovers and develops therapies targeting protein homeostasis | Health Technology |
Kronos Bio, Inc.
Kronos Bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops novel cancer therapeutics | Health Technology |
- Stock Market
- Insiders
- Zung To
















